Opportunities and challenges in the treatment of IgA nephropathy
The treatment paradigm of immunoglobulin A nephropathy (IgAN) is shifting, and traditional therapeutic strategies are insufficient to meet clinical needs. Based on the increasing understanding of the pathogenesis of IgAN, current treatment goals concentrate on anti-inflammatory and targeted therapy,...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1559593/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849420010344153088 |
|---|---|
| author | Yang Yang Yang Yang Gaosi Xu |
| author_facet | Yang Yang Yang Yang Gaosi Xu |
| author_sort | Yang Yang |
| collection | DOAJ |
| description | The treatment paradigm of immunoglobulin A nephropathy (IgAN) is shifting, and traditional therapeutic strategies are insufficient to meet clinical needs. Based on the increasing understanding of the pathogenesis of IgAN, current treatment goals concentrate on anti-inflammatory and targeted therapy, as well as optimizing therapy. New therapeutic approaches are being developed, including complement inhibitors, B-cell activating factor and a proliferation-inducing ligand inhibitor, and endothelin receptor antagonists. Further supportive care showed promising prospects and combination therapy such as sodium-glucose cotransporter 2 inhibitor with endothelin receptor antagonists are also being investigated, which may provide greater benefit. IgAN is a disease that requires lifelong management, the treatment choices faced may be inconsistent at different ages and periods. With the emerging opportunities in IgAN treatment, achieving individualized precision therapy is a key challenge currently facing research institues. This review summarizes recent advances in the treatment of IgAN and discusses possible therapeutic strategies for IgAN patients. |
| format | Article |
| id | doaj-art-9082147d7e9c4911bca8098e18c65475 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-9082147d7e9c4911bca8098e18c654752025-08-20T03:31:53ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-07-011610.3389/fphar.2025.15595931559593Opportunities and challenges in the treatment of IgA nephropathyYang Yang0Yang Yang1Gaosi Xu2Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, ChinaJiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, ChinaThe treatment paradigm of immunoglobulin A nephropathy (IgAN) is shifting, and traditional therapeutic strategies are insufficient to meet clinical needs. Based on the increasing understanding of the pathogenesis of IgAN, current treatment goals concentrate on anti-inflammatory and targeted therapy, as well as optimizing therapy. New therapeutic approaches are being developed, including complement inhibitors, B-cell activating factor and a proliferation-inducing ligand inhibitor, and endothelin receptor antagonists. Further supportive care showed promising prospects and combination therapy such as sodium-glucose cotransporter 2 inhibitor with endothelin receptor antagonists are also being investigated, which may provide greater benefit. IgAN is a disease that requires lifelong management, the treatment choices faced may be inconsistent at different ages and periods. With the emerging opportunities in IgAN treatment, achieving individualized precision therapy is a key challenge currently facing research institues. This review summarizes recent advances in the treatment of IgAN and discusses possible therapeutic strategies for IgAN patients.https://www.frontiersin.org/articles/10.3389/fphar.2025.1559593/fullimmunoglobulin A nephropathygalactose-deficient IgA1treatmentnefeconsparsentan |
| spellingShingle | Yang Yang Yang Yang Gaosi Xu Opportunities and challenges in the treatment of IgA nephropathy Frontiers in Pharmacology immunoglobulin A nephropathy galactose-deficient IgA1 treatment nefecon sparsentan |
| title | Opportunities and challenges in the treatment of IgA nephropathy |
| title_full | Opportunities and challenges in the treatment of IgA nephropathy |
| title_fullStr | Opportunities and challenges in the treatment of IgA nephropathy |
| title_full_unstemmed | Opportunities and challenges in the treatment of IgA nephropathy |
| title_short | Opportunities and challenges in the treatment of IgA nephropathy |
| title_sort | opportunities and challenges in the treatment of iga nephropathy |
| topic | immunoglobulin A nephropathy galactose-deficient IgA1 treatment nefecon sparsentan |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1559593/full |
| work_keys_str_mv | AT yangyang opportunitiesandchallengesinthetreatmentofiganephropathy AT yangyang opportunitiesandchallengesinthetreatmentofiganephropathy AT gaosixu opportunitiesandchallengesinthetreatmentofiganephropathy |